ZBTB7A and glioblastoma: In contrast, the metastatic ability of the TMED3-KD + ZBTB7A-OE group was greater than that of the TMED3-KD + sh-NC group (P < 0.05), demonstrating that ZBTB7A overexpression reversed the inhibitory effect of TMED3 knockdown on the invasive capacity of GBM cells (Fig. 6d, e).